accounts disease drug dimebon in a late-stage trial. More from Adam Feuerstein Market Activity Medivation Inc.| MDVN Pfizer Inc.| PFE Investors have been focused on Medivation's promising prostate cancer drug MDV3100, essentially writing off the future of...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Investors Shrug Off Medivation Setback
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account